Close Menu

Gentris

NEW YORK (GenomeWeb) – Cancer Genetics today announced it has signed a non-binding letter of intent to buy Gentris for up to $6.25 million.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said in its recently filed Form 10-Q that it identified errors in financial statements starting in 2008 through the second quarter of 2013 related to the valuation of finished goods inventory in the company's Life Science segment.

Qlucore has added three new employees to its staff.

Gentris last week expanded its genomic biomarker offering to include Affymetrix GeneChip Human Transcriptome Array services.

NEW YORK (GenomeWeb News) – Nanosphere this week received the CE IVD Mark for its Gram-Negative Blood Culture test that runs on the firm's Verigene molecular diagnostics platform.

NEW YORK (GenomeWeb News) – Idaho Technology has changed its name to BioFire Diagnostics.

NEW YORK (GenomeWeb News) – Becton Dickinson said this week it has declared a quarterly dividend of $45 per share, payable on Sept. 28 to shareholders of record on Sept. 7. The indicated annual dividend rate is $1.80 per share.

Gentris will now offer Affymetrix's DMET Plus as one of its pharmacogenomics services.

NEW YORK (GenomeWeb News) – Gentris and the Shanghai Institutes of Preventative Medicine have signed a memorandum of understanding to collaborate on personalized medicine initiatives.

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.